Legal & General Group
TXMD icon

Legal & General Group’s TherapeuticsMD TXMD Stock Holding History

Legal & General Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-796
Closed -$15K – 3657
2022
Q1 		$15K Buy
796
+11
+1% +$173 ﹤0.01% 3305
2021
Q4 		$14K Sell
785
-4,208
-84% -$126K ﹤0.01% 3388
2021
Q3 		$185K Buy
4,993
+1,476
+42% +$65.5K ﹤0.01% 2718
2021
Q2 		$210K Buy
3,517
+2,065
+142% +$125K ﹤0.01% 2528
2021
Q1 		$97K Buy
1,452
+560
+63% +$43.8K ﹤0.01% 2630
2020
Q4 		$54K Hold
892
– – ﹤0.01% 2778
2020
Q3 		$70K Sell
892
-1,324
-60% -$106K ﹤0.01% 2588
2020
Q2 		$139K Buy
2,216
+5
+0.2% +$291 ﹤0.01% 2445
2020
Q1 		$118K Sell
2,211
-177
-7% -$17.5K ﹤0.01% 2367
2019
Q4 		$289K Buy
2,388
+229
+11% +$32.9K ﹤0.01% 2319
2019
Q3 		$392K Buy
2,159
+215
+11% +$30.3K ﹤0.01% 2213
2019
Q2 		$253K Buy
1,944
+65
+3% +$11.7K ﹤0.01% 2288
2019
Q1 		$458K Buy
1,879
+68
+4% +$18K ﹤0.01% 2173
2018
Q4 		$345K Buy
1,811
+577
+47% +$141K ﹤0.01% 2199
2018
Q3 		$405K Buy
1,234
+45
+4% +$13.8K ﹤0.01% 2184
2018
Q2 		$371K Sell
1,189
-85
-7% -$26K ﹤0.01% 2172
2018
Q1 		$310K Buy
1,274
+83
+7% +$23.3K ﹤0.01% 2221
2017
Q4 		$359K Sell
1,191
-43
-3% -$12K ﹤0.01% 2167
2017
Q3 		$324K Buy
1,234
+109
+10% +$31.5K ﹤0.01% 2193
2017
Q2 		$298K Buy
1,125
+69
+7% +$17.3K ﹤0.01% 2177
2017
Q1 		$381K Sell
1,056
-13
-1% -$4.02K ﹤0.01% 2098
2016
Q4 		$309K Buy
1,069
+319
+43% +$98.9K ﹤0.01% 2104
2016
Q3 		$252K Sell
750
-79
-10% -$28.9K ﹤0.01% 1974
2016
Q2 		$354K Hold
829
– – ﹤0.01% 1521
2016
Q1 		$266K Buy
829
+310
+60% +$106K ﹤0.01% 1626
2015
Q4 		$276K Buy
519
+61
+13% +$22.5K ﹤0.01% 1605
2015
Q3 		$135K Buy
458
+162
+55% +$57.6K ﹤0.01% 1883
2015
Q2 		$115K Hold
296
– – ﹤0.01% 2020
2015
Q1 		$90K Hold
296
– – ﹤0.01% 2109
2014
Q4 		$64K Hold
296
– – ﹤0.01% 2288
2014
Q3 		$70K Buy
+296
New +$74.6K ﹤0.01% 2166

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Legal & General Group's TXMD Position: Q2 2022 in Review

Legal & General Group sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 796 shares — an estimated $15K sold.

Legal & General Group first reported a position in TXMD in Q3 2014 and held it in 31 quarters. The position peaked at $458K in Q1 2019. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Legal & General Group reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Legal & General Group sold 796 TherapeuticsMD shares in Q2 2022, an estimated $15K.
  • Legal & General Group first reported a position in TherapeuticsMD in Q3 2014 and held it in 31 quarters.
  • Legal & General Group's TherapeuticsMD position peaked at $458K in Q1 2019.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Legal & General Group's 13F filing for Q2 2022, filed 22 Aug 2022.